Novavax says the COVID vaccine triggers an immune response to the Omicron variant

According to early results published on Wednesday, Novavax Inc’s (NVAX.O) COVID-19 vaccine is efficient in eliciting an immune response against the Omicron variation, implying that the US drugmaker’s existing COVID-19 vaccine can help tackle the new Omicron form.

Read More